Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EBITDA (2017 - 2025)

Crinetics Pharmaceuticals has reported EBITDA over the past 9 years, most recently at -$123.1 million for Q4 2025.

  • Quarterly results put EBITDA at -$123.1 million for Q4 2025, down 50.78% from a year ago — trailing twelve months through Dec 2025 was -$464.4 million (down 55.62% YoY), and the annual figure for FY2025 was -$464.4 million, down 55.62%.
  • EBITDA for Q4 2025 was -$123.1 million at Crinetics Pharmaceuticals, up from -$129.5 million in the prior quarter.
  • Over the last five years, EBITDA for CRNX hit a ceiling of -$22.9 million in Q1 2021 and a floor of -$129.5 million in Q3 2025.
  • Median EBITDA over the past 5 years was -$53.4 million (2023), compared with a mean of -$62.4 million.
  • Biggest five-year swings in EBITDA: fell 14.54% in 2023 and later crashed 73.62% in 2025.
  • Crinetics Pharmaceuticals' EBITDA stood at -$31.2 million in 2021, then tumbled by 40.91% to -$43.9 million in 2022, then crashed by 32.66% to -$58.3 million in 2023, then crashed by 40.19% to -$81.7 million in 2024, then plummeted by 50.78% to -$123.1 million in 2025.
  • The last three reported values for EBITDA were -$123.1 million (Q4 2025), -$129.5 million (Q3 2025), and -$116.0 million (Q2 2025) per Business Quant data.